Karyopharm spotlights PhIII results after controversial FDA approval
There are mountain ranges with less jagged curves than Karyopharm’s stock $KPTI.
Over the last year, the biotech has risen and cratered and risen again as a debate over whether its lead drug is safe — or even works — played out in public FDA reviews and advisory committee hearings. But after a skeptical internal review from the agency noted previously undisclosed trial deaths and a solid majority of outside advisors voted to reject the drug, Karyopharm emerged in July with a surprise accelerated approval for selinexor, now called Xpovio.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,600+ biopharma pros reading Endpoints daily — and it's free.